Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MNLO pudufa biotech diamond at this level. they have a approved drug. In may we will see first revenues from this drug.
Also pudufa data ph3 at 6/2
Lowfloater
Cash per share 1.18
Book value at 3$
Mk only 84M
Float 53M
2.5M are short
MNLO pudufa biotech diamond at this level. they have a approved drug. In may we will see first revenues from this drug.
Also pudufa data ph3 at 6/2
Lowflaoter
MNLO cheap @this level they have a approved drug. In may we will see first revenues from this drug.
Also pudufa data ph3 at 6/2
Lowflaoter
Yes looking good also insider bought in big.
Daily buyer still on the buy trigger.
MYOV this month over 20$ big insider buying every day checkout the filling s
MYOV this month over 20$ big insider buying every day checkout the filling s
PLX lowfloater on the move. 4$ breaking than main target to break the downtrend since 2017 at 4.20$
PLX lowfloater on the move. 4$ breaking than main target to break the downtrend since 2017 at 4.20$
PLX #chartcheck #weekly #signaljumper #biotech #volume
Key point is to break the downtrend since 2017. Key point is 4.20$ to break. $MN was also a breakout above their longtime downtend and this stock is also a lowfloater.
MACD near a buy trigger
RSI turning up
chart:
chart
PLX #chartcheck #weekly #signaljumper #biotech #volume
Key point is to break the downtrend since 2017. Key point is 4.20$ to break. $MN was also a breakout above their longtime downtend and this stock is also a lowfloater.
MACD near a buy trigger
RSI turning up
chart:
chart
PLX BLA news are also in pipline now up near 5% this low floater can run very fast. Check the daily chart.
The weekly chart looks ready and a lot of room to move.
PLX BLA news are also in pipline now up near 5% this low floater can run very fast. Check the daily chart.
The weekly chart looks ready and a lot of room to move.
CDTX covid19 play near key level at 3$ not man Mm to 3$ breakout
CDTX covid19 play near key level at 3$ not man Mm to 3$ breakout
PLX must read from last Q
We are increasingly enthusiastic about our PRX-102 asset now that we have three ongoing, fully-enrolled Phase III clinical trials of PRX-102, and as we anticipate our BLA submission to the U.S. Food and Drug Administration under the Accelerated Approval pathway next quarter," added Mr. Bashan. "Furthermore, we anticipate the final results of our BRIDGE and BRIGHT trials in the first and second halves of 2020, respectively, which will further support our portfolio of data regarding PRX-102. Protalix is firing on all cylinders right now, and the energy among the entire staff reached a new pinnacle in 2019."
"We anticipate 2020 to be a banner year for Protalix as we increase our focus on advancing our clinical pipeline, expanding sales in Brazil of Elelyso®, our enzyme replacement therapy for the treatment of Gaucher disease, and leveraging commercial opportunities to expand our global footprint in the treatment of Fabry disease," he concluded.
PLX must read from last Q
We are increasingly enthusiastic about our PRX-102 asset now that we have three ongoing, fully-enrolled Phase III clinical trials of PRX-102, and as we anticipate our BLA submission to the U.S. Food and Drug Administration under the Accelerated Approval pathway next quarter," added Mr. Bashan. "Furthermore, we anticipate the final results of our BRIDGE and BRIGHT trials in the first and second halves of 2020, respectively, which will further support our portfolio of data regarding PRX-102. Protalix is firing on all cylinders right now, and the energy among the entire staff reached a new pinnacle in 2019."
"We anticipate 2020 to be a banner year for Protalix as we increase our focus on advancing our clinical pipeline, expanding sales in Brazil of Elelyso®, our enzyme replacement therapy for the treatment of Gaucher disease, and leveraging commercial opportunities to expand our global footprint in the treatment of Fabry disease," he concluded.
PLX a lot of insider buying in also insti. Investors. NDA, phase3 data should come out soon.
Stock is a lowfloater and broke out above the downtrend
PLX a lot of insider buying in also insti. Investors. NDA, phase3 data should come out soon.
Stock is a lowfloater and broke out above the downtrend
PLX a lot of insider buying in also insti. Investors. NDA, phase3 data should come out soon.
Stock is a lowfloater and broke out above the downtrend
Lawfirms are on it so no stock for me
I'm out but with the last filling and the filling from today could be that we will see a buyout or takeover on MN
My call on MN was a nice running. Today I cashed in. Could run a little bit more but cash is cash
Called it @1.21 at Twitter
MN good consolidation now next wave ready 3$ is the key. When u check the short interest there is no change so 6% from float are still short.
$MN up over 60% still the beginning
Check out the bookvalue and cashvalue. Only 5 million in free float
Thanx. MLND will be next 3.99 bookvalue cash value 3.43
Today up 20% not much people following this stock.
It crashed because bad ph2 data.
But the have a second phase 2b drug in play. So perfect entry under bookvalue.
MN only 5.4M tradeable 60% are in insider and inst. Own. Hands
Free float are 13.7M
Short. 5.7%
MN I think this is just the beginning
Forward PE at 9 is low also Dividende full year of around 8cent
Is also very good.
3$ than 4$
MN hit new 52 week highs volume
Incrise 90%
MN looking strong this lowfloater.
My target 3$+
2.50$ break will be good to bring the shorts in trouble
MLND breaking out this sto k falls down on ph2b bad results.
But the have another ph2b drug in play
Bookvalue is 3.99
And cash value at 3.42 $
I think soon we will move over 3$
This drop under the Cas value and bookvalue was an overreactio because we have still a good drug in the pipline.
MLND breaking out this sto k falls down on ph2b bad results.
But the have another ph2b drug in play
Bookvalue is 3.99
And cash value at 3.42 $
I think soon we will move over 3$
This drop under the Cas value and bookvalue was an overreactio because we have still a good drug in the pipline.
MN breaking out lowfloater on the move should see 3$ very quick
MN ready to move 2$ is the downtrend could break soon. Lowfloater that pay Dividende
MN Check it out a lowfloater beginning to move. Also pay Dividende. 2$ breaking and we are breaking out above the 3 years downtrend
MN Check it out a lowfloater beginning to move. Also pay Dividende. 2$ breaking and we are breaking out above the 3 years downtrend
CPE oil stock were insider buying since 2 month this stock will run hard
MLND 1.40 trading under cash value 3.39 and book value is 3.99
Bad news drop it down from ph2b data.
But they still have 1 iron in the die
Also ph2b data expected 2h2020
Cash holding till 2022
MLND 1.40 trading under cash value 3.39 and book value is 3.99
Bad news drop it down from ph2b data.
But they still have 1 iron in the die
Also ph2b data expected 2h2020
Cash holding till 2022